# Study to Evaluate Safety, PK, PD, Immunogenicity & Antitumor Activity of MSC-1 in Patients With Adv Solid Tumors

> **NCT03490669** · PHASE1 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 41 (actual)

## Conditions studied

- Advanced Solid Tumors
- Pancreatic Cancer
- Non Small Cell Lung Cancer
- Ovarian Cancer

## Interventions

- **BIOLOGICAL:** MSC-1

## Key facts

- **NCT ID:** NCT03490669
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-05-21
- **Primary completion:** 2019-09-23
- **Final completion:** 2019-09-23
- **Target enrollment:** 41 (ACTUAL)
- **Last updated:** 2024-04-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03490669

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03490669, "Study to Evaluate Safety, PK, PD, Immunogenicity & Antitumor Activity of MSC-1 in Patients With Adv Solid Tumors". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03490669. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*